Eli Lilly acquires inflammatory specialist Ventyx for $1.2bn
Eli Lilly has agreed to acquire autoimmune oral drug developer Ventyx Biosciences, representing the big pharma company’s latest push to…
08 Jan 2026
GSK to file for approval of twice-yearly hep B drug on positive Phase III data
GSK’s six-monthly triple-action investigational antisense oligonucleotide (ASO) candidate has demonstrated a clinically and statistically significant functional cure in chronic hepatitis B in two Phase III trials. The B-Well 1 (NCT05630807)…
08 Jan 2026
Octapharma receives FDA approval for new Fibryga formulation in AFD
Octapharma has received approval from the US Food and Drug Administration (FDA) for a new 2-gram (g) formulation of Fibryga for use in patients with acquired fibrinogen deficiency (AFD). The…
08 Jan 2026
Day One concludes Mersana Therapeutics acquisition
Day One Biopharmaceuticals has concluded its acquisition of Mersana Therapeutics after meeting all the tender offer conditions. The tender offer expired on 5 January 2026. The transaction involved purchasing all…
07 Jan 2026
Amgen buys Dark Blue Therapeutics in $840m oncology deal
Amgen has agreed to acquire UK-based biotech Dark Blue Therapeutics for up to $840m, making it the first pharma takeover of 2026. Through this transaction, Amgen will gain access to…
07 Jan 2026
Eli Lilly signs $1.3bn obesity-focused research deal with Nimbus
Eli Lilly has signed a research and licence agreement with Nimbus Therapeutics, aiming to develop a new oral weight loss drug, deepening ties between the two companies. The latest partnership…
07 Jan 2026
Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis
Cellenkos has received orphan drug designation from the US Food and Drug Administration (FDA) for its investigational CK0804 regulatory T cell (Treg) therapy to treat myelofibrosis, a rare blood cancer. The…